Literature DB >> 10992946

Optimum imaging for sinonasal malignancy.

G Lloyd1, V J Lund, D Howard, L Savy.   

Abstract

A combination of computed tomography (CT) and magnetic resonance imaging (MRI) is now established as the optimum assessment of sinonasal malignancy. CT and MRI are of particular value in assessing the skull base, orbit and pteryo-palatine and infratemporal fossae. Although MRI offers better differentiation of tumour from surrounding tissue and fluid, coronal CT is still required for the demonstration of bone erosion particularly in the region of the cribriform plate. Thus the extent of local tumour spread may be determined with a degree of accuracy in excess of 98 per cent. However, the final determinant of penetration of the dura and orbital periosteum requires per-operative frozen section assessment. A knowledge of the tissue characteristics and site of origin can be of value in distinguishing some of the commoner sinonasal malignancies such as squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, olfactory neuroblastoma and chondrosarcoma. Imaging, particularly MRI also plays an important role in the post-therapeutic follow-up of patients, indicating areas of residual or recurrent disease, defining suspicious areas for biopsy. Post-operative surveillance is best achieved with three planar T1-weighted MRI, with, and without, gadolinium and axial T2-weighted sequences. The subtraction of the T1 pre- and post gadolinium T1 sequences can be of particular value in delineating recurrence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10992946     DOI: 10.1258/0022215001906174

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  10 in total

Review 1.  Radiological imaging of inflammatory lesions in the nasal cavity and paranasal sinuses.

Authors:  H B Eggesbø
Journal:  Eur Radiol       Date:  2006-01-04       Impact factor: 5.315

2.  Myxoid chondrosarcoma of the maxilla in a pediatric patient.

Authors:  Sabine Jörg; Christian August; Wolfgang Stoll; Jürgen Alberty
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-07-09       Impact factor: 2.503

3.  [Malignant paranasal sinus tumors. Diagnosis, therapy and results].

Authors:  G Baier; C Völter; I Steigerwald; J Müller; K Schwager
Journal:  HNO       Date:  2005-11       Impact factor: 1.284

4.  Nasosinusal chondrosarcoma with orbito-cerebral extension.

Authors:  Khalid Bouhafs; Azeddine Lachkar; Tayeb Bouamama; Achraf Miry; Drissia Benfadil; Mohammed Rachid Ghailan
Journal:  J Surg Case Rep       Date:  2022-06-22

5.  Role of diagnostic imaging to malignant sinus tumors in presurgical staging.

Authors:  E Fanucci; V Fiaschetti; N Fusco; S Viarani; M Gargari; A Barlattani; E P Assako; G Simonetti
Journal:  Oral Implantol (Rome)       Date:  2009-02-01

6.  Sinonasal malignancies: a 10-year review in a tertiary health institution.

Authors:  Ayotunde J Fasunla; Akeem O Lasisi
Journal:  J Natl Med Assoc       Date:  2007-12       Impact factor: 1.798

7.  Sinonasal tract and nasopharyngeal adenoid cystic carcinoma: a clinicopathologic and immunophenotypic study of 86 cases.

Authors:  Lester D R Thompson; Carla Penner; Ngoc J Ho; Robert D Foss; Markku Miettinen; Jacqueline A Wieneke; Christopher A Moskaluk; Edward B Stelow
Journal:  Head Neck Pathol       Date:  2013-09-15

8.  Sinonasal Chondrosarcoma, an Unusual Location.

Authors:  Oumniya Abouhanine; Aicha Merzem; Vianney Ndayishimiye; Omar Amriss; Hasnaa Belgadir; Nadia Moussali; Naima El Benna
Journal:  Eur J Case Rep Intern Med       Date:  2020-11-11

Review 9.  [Naso-sinusal chondrosarcoma: report of two cases and review of the literature].

Authors:  Mohamed Mliha Touati; Mehdi Chihani; Youssef Darouassi; Mohammed Lakouichmi; Khalid Tourabi; Brahim Bouaity; Haddou Ammar
Journal:  Pan Afr Med J       Date:  2014-10-17

10.  Sinonasal undifferentiated carcinoma presenting as recurrent fronto-ethmoidal pyomucocele.

Authors:  Sushil Kumar Aggarwal; Amit Keshri
Journal:  Natl J Maxillofac Surg       Date:  2012-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.